137 related articles for article (PubMed ID: 19147680)
1. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
Higashi Y; Holder K; Delafontaine P
J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
Chen Z; Vigueira PA; Chambers KT; Hall AM; Mitra MS; Qi N; McDonald WG; Colca JR; Kletzien RF; Finck BN
J Biol Chem; 2012 Jul; 287(28):23537-48. PubMed ID: 22621923
[TBL] [Abstract][Full Text] [Related]
4. Effects of telmisartan on metabolic syndrome components: a comprehensive review.
Imenshahidi M; Roohbakhsh A; Hosseinzadeh H
Biomed Pharmacother; 2024 Feb; 171():116169. PubMed ID: 38228033
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan inhibits microglia-induced neurotoxic A1 astrocyte conversion via PPARγ-mediated NF-κB/p65 degradation.
Quan W; Xu CS; Li XC; Yang C; Lan T; Wang MY; Yu DH; Tang F; Wang ZF; Li ZQ
Int Immunopharmacol; 2023 Oct; 123():110761. PubMed ID: 37544025
[TBL] [Abstract][Full Text] [Related]
6. Effects of Three Thiazolidinediones on Metabolic Regulation and Cold-Induced Thermogenesis.
Sohn JH; Kim JI; Jeon YG; Park J; Kim JB
Mol Cells; 2018 Oct; 41(10):900-908. PubMed ID: 30145862
[TBL] [Abstract][Full Text] [Related]
7. The protective role of peroxisome proliferator-activated receptor gamma in lipotoxic podocytes.
Carrasco AG; Izquierdo-Lahuerta A; Valverde ÁM; Ni L; Flores-Salguero E; Coward RJ; Medina-Gómez G
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Jul; 1868(7):159329. PubMed ID: 37156296
[TBL] [Abstract][Full Text] [Related]
8. PPARγ activation inhibits growth and survival of human endometriotic cells by suppressing estrogen biosynthesis and PGE2 signaling.
Lebovic DI; Kavoussi SK; Lee J; Banu SK; Arosh JA
Endocrinology; 2013 Dec; 154(12):4803-13. PubMed ID: 24064359
[TBL] [Abstract][Full Text] [Related]
9. Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver.
Ebihara C; Aizawa-Abe M; Zhao M; Gumbilai V; Ebihara K
Sci Rep; 2022 Jan; 12(1):449. PubMed ID: 35013417
[TBL] [Abstract][Full Text] [Related]
10. Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease.
Lee SM; Muratalla J; Sierra-Cruz M; Cordoba-Chacon J
J Endocrinol; 2023 Apr; 257(1):. PubMed ID: 36688873
[TBL] [Abstract][Full Text] [Related]
11. Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity.
Ayza MA; Zewdie KA; Tesfaye BA; Gebrekirstos ST; Berhe DF
Diabetes Metab Syndr Obes; 2020; 13():3627-3635. PubMed ID: 33116714
[TBL] [Abstract][Full Text] [Related]
12. PPARγ signaling and metabolism: the good, the bad and the future.
Ahmadian M; Suh JM; Hah N; Liddle C; Atkins AR; Downes M; Evans RM
Nat Med; 2013 May; 19(5):557-66. PubMed ID: 23652116
[TBL] [Abstract][Full Text] [Related]
13. In vitro Screening and Evaluation of 37 Traditional Chinese Medicines for Their Potential to Activate Peroxisome Proliferator-Activated Receptors-γ.
Gao D; Zhang Y; Yang F; Lin Y; Zhang Q; Xia Z
Pharmacogn Mag; 2016; 12(46):120-7. PubMed ID: 27076748
[TBL] [Abstract][Full Text] [Related]
14. The Role of PPARgamma in pulmonary vascular disease.
Hart CM
J Investig Med; 2008 Feb; 56(2):518-21. PubMed ID: 18317434
[TBL] [Abstract][Full Text] [Related]
15. Harnessing peroxisome proliferator-activated receptor γ agonists to induce Heme Oxygenase-1: a promising approach for pulmonary inflammatory disorders.
Lee IT; Yang CC; Yang CM
Cell Commun Signal; 2024 Feb; 22(1):125. PubMed ID: 38360670
[TBL] [Abstract][Full Text] [Related]
16. New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.
Jia Z; Sun Y; Yang G; Zhang A; Huang S; Heiney KM; Zhang Y
PPAR Res; 2014; 2014():818530. PubMed ID: 24624137
[TBL] [Abstract][Full Text] [Related]
17. Unveiling clinically significant PPARγ mutations for thiazolidinedione treatment responsiveness through atomistic simulations.
Shahrear S; Islam ABMMK
Int J Biol Macromol; 2023 Dec; 253(Pt 4):126990. PubMed ID: 37741483
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Angiotensin Receptor Blockers in a Pre-Clinical Model of Arrhythmogenic Cardiomyopathy.
Landim-Vieira M; Kahmini AR; Engel M; Cannon EN; Amat-Alarcon N; Judge DP; Pinto JR; Chelko SP
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430389
[TBL] [Abstract][Full Text] [Related]
19. Metabolites of endophytic fungi isolated from leaves of
Mesquita PG; de Araujo LM; Neves FAR; Borin MF
Front Fungal Biol; 2022; 3():1049690. PubMed ID: 37746194
[No Abstract] [Full Text] [Related]
20. PPARγ in Atherosclerotic Endothelial Dysfunction: Regulatory Compounds and PTMs.
Luan J; Ji X; Liu L
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
